These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1087 related articles for article (PubMed ID: 24315327)

  • 1. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.
    Rothery C; Strong M; Koffijberg HE; Basu A; Ghabri S; Knies S; Murray JF; Sanders Schmidler GD; Steuten L; Fenwick E
    Value Health; 2020 Mar; 23(3):277-286. PubMed ID: 32197720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of information analyses of economic randomized controlled trials: the treatment of intermittent claudication.
    Groot Koerkamp B; Spronk S; Stijnen T; Hunink MG
    Value Health; 2010; 13(2):242-50. PubMed ID: 19818058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The option value of delay in health technology assessment.
    Eckermann S; Willan AR
    Med Decis Making; 2008; 28(3):300-5. PubMed ID: 18480035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme.
    Claxton K; Ginnelly L; Sculpher M; Philips Z; Palmer S
    Health Technol Assess; 2004 Jul; 8(31):1-103, iii. PubMed ID: 15248937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Decision Makers' Constraints on the Outcome of Value of Information Analysis.
    Koffijberg H; Knies S; Janssen MP
    Value Health; 2018 Feb; 21(2):203-209. PubMed ID: 29477402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.
    McCullagh L; Walsh C; Barry M
    Pharmacoeconomics; 2012 Oct; 30(10):941-59. PubMed ID: 22667458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research.
    Oostenbrink JB; Al MJ; Oppe M; Rutten-van Mölken MP
    Value Health; 2008 Dec; 11(7):1070-80. PubMed ID: 19602213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness and value of information analysis of nutritional support for preventing pressure ulcers in high-risk patients: implement now, research later.
    Tuffaha HW; Roberts S; Chaboyer W; Gordon LG; Scuffham PA
    Appl Health Econ Health Policy; 2015 Apr; 13(2):167-79. PubMed ID: 25650349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of research and value of development in early assessments of new medical technologies.
    Retèl VP; Grutters JP; van Harten WH; Joore MA
    Value Health; 2013; 16(5):720-8. PubMed ID: 23947964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
    Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
    Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
    Buyukkaramikli NC; Wigfield P; Hoang MT
    Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of value of information in UK health technology assessments.
    Mohiuddin S; Fenwick E; Payne K
    Int J Technol Assess Health Care; 2014 Dec; 30(6):553-70. PubMed ID: 25816821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of value of information: best informing research design and prioritization using current methods.
    Eckermann S; Karnon J; Willan AR
    Pharmacoeconomics; 2010; 28(9):699-709. PubMed ID: 20629473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of information: interim analysis of a randomized, controlled trial of goal-directed hemodynamic treatment for aged patients.
    Bartha E; Davidson T; Brodtkorb TH; Carlsson P; Kalman S
    Trials; 2013 Jul; 14():205. PubMed ID: 23837606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing value of information analyses.
    Janssen MP; Koffijberg H
    Value Health; 2009 Sep; 12(6):935-41. PubMed ID: 19432841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prioritizing Research Informing Antibiotic Prophylaxis Guidelines for Knee Arthroplasty Patients.
    Kuntz KM; Alarid-Escudero F; Swiontkowski MF; Skaar DD
    JDR Clin Trans Res; 2022 Jul; 7(3):298-306. PubMed ID: 34137291
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 55.